Intel backs Mylan's anti-Fintiv SCOTUS stance
16-09-2021
Mylan, Edwards back NHK-Fintiv challenge
31-08-2021
Janssen sues Mylan to block generic of schizophrenia drug
29-09-2020
EPO revokes Copaxone patent, clears path for Mylan
17-09-2020
ricochet64 / Shutterstock.com
Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Mylan Laboratories, NHK-Fintive, PTAB, SCOTUS, USPTO
